Pharmaceutical major Zydus Cadila has told the Centre that it could apply for emergency use authorisation (EUA) for ZyCoV-D vaccine in the next seven-eight days.
It will be the second indigenous Covid-19 vaccine to apply for such authorisation. It will also be the world's first DNA vaccine against coronavirus.
"Zydus Cadila has told the government that it could apply for emergency use authorisation for ZyCoV-D vaccine in the next seven-eight days," a government source said.
ZyCoV-D is a DNA Covid vaccine, which carries the genetic code for that part of a virus that triggers the immune system of the body.
Niti Aayog Member (Health) Dr VK Paul told ANI that Cydus Cadila has enrolled more than 28,000 volunteers for their phase three study.
"We are hoping that they will apply in near future. Most of their study is complete. They have enrolled more than 28,000 volunteers in their phase 3 study. We expect they will submit the results very soon. We are hopeful of this vaccine because it would be the world's first DNA vaccine. We are very proud of their work," he said.
The vaccine is being developed with support from the Centre's National Biopharma Mission as part of the Biotechnology Industry Research Assistance Council, Department of Biotechnology.
India has approved three vaccines against COVID-19 -- Covaxin (Bharat Biotech), Covishield (Serum Institute), and the Russian Sputnik V.
Covishield has been developed by AstraZeneca and Oxford University.
ZyCoV-D, the second indigenous vaccine after Bharat Biotech's Covaxin, is a three-dose vaccine -- to be administered at day 0, day 28, and day 56. The company has said it is also working on a two-dose regimen of this vaccine.
The stability data of the vaccine candidate showed that ZyCoV-D can be stored at 2 to 8 degrees Celsius for long-term use and 25 degrees Celsius for the short term.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU